It demonstrated that increasing mutational load was associated with higher response rate to anti–CTLA-4 in melanoma and anti–PD-1 in lung cancer, indicating that the recognition of mutated neoantigen plays a crucial part in the antitumor immune response [48]. The gene discussed is CTLA4; the disease is lung cancer.